AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01709513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for alirocumab, ezitimibe and atorvastatin.
Trial: NCT04442945
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: NCT02268903
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in one single direct intra venous injection
Trial: NCT03970447
Drug: VT1021
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: Infusion for intravenous administration Strength: 10 mg/mL Standard Regimen Newly Diagnosed: Dose as confirmed through the dose finding phase, administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri).~Standard Regimen Recurrent: 12 mg/kg administered twice weekly (Mon and Thurs or Tues and Fri or Mon and Fri). The drug is available as a sterile solution of the acetate salt formulated with phosphate-buffered saline, mannitol, and 2.5% polysorbate 80. The required volume stock solution for the patient is calculated. The corresponding volume is diluted in 500 mL of either 0.9% saline or D5W, prior to intravenous administration.
Trial: NCT02575950
Drug: LEO43204
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02575950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04574583
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive M7824 at a flat dose of 1,200 mg intravenously on Days 1 and 15 of each cycle.
Trial: NCT03686033
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive E2082-matched placebo tablets orally.
Trial: NCT01045161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
Trial: NCT01911676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00102973
Drug: Doxorubicin HCl Liposome Injection
RxNorm normalized name: DOXORUBICIN HYDROCHLORIDE LIPOSOME
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT01970371
Drug: tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01970371
Drug: antibiotic of Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02442128
Drug: propofol /Fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Trial: NCT02442128
Drug: Fentanyl / propofol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
Trial: NCT00870441
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00870441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03797014
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose combination B/F/TAF (50 mg/ 200 mg/ 25 mg/ tablet) administered orally once daily without regards to food.
Trial: NCT01433575
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg single oral dose
Trial: NCT01433575
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg single oral dose
Trial: NCT00424424
Drug: MK0719
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04458298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo infusion will be administered intravenously.
Trial: NCT01001403
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of normal saline
Trial: NCT03994172
Drug: placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo tablet in the trial will be purchased from Consolidated Midland Corporation in Brewster, NY. Each white tablet contains Lactose, Stearic Acid and Magnesium Stearate (330 mg total). Subjects randomized to the placebo arm or Placebo - Arm #2 - will take one tablet orally at the same time as he injects the teriparatide each day. Placebo tablets will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
Trial: NCT03715881
Drug: Oral prednisolone administration 50 mg
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
Trial: NCT00844753
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + parent management treatment
Trial: NCT02142777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo has no active ingredients but is made to look like the study drug.
Trial: NCT01950000
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02446431
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
Trial: NCT01348269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl Solution
Trial: NCT01468272
Drug: CHF 1535 50/6 NEXT DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
Trial: NCT03332485
Drug: ECP Colon Prep Kit
RxNorm normalized name: Sus scrofa colon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ECP Colon Prep Kit
Trial: NCT03332485
Drug: MoviPrep®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MoviPrep®
Trial: NCT01553981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shape , size, color and odor matched Tab. of inert material every other day for 6 months
Trial: NCT04155671
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
Trial: NCT04155671
Drug: FOLFOX plus PAC(ip)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX plus intraperitoneally paclitaxel
Trial: NCT05512546
Drug: Aspir-Low Pill
RxNorm normalized name: Aspir-Low Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients were prescribed 75 mg/day of either aspirin
Trial: NCT02300701
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03381716
Drug: drug
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application bracket
Trial: NCT01439555
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin, 40 mg per day orally
Trial: NCT00376870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30 mg/d
Trial: NCT02781909
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
Trial: NCT00085956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03784079
Drug: GSK3640254
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3640254 will be available with dosing strengths of 5 mg, 20 mg, and 100 mg to be administered as an oral capsule along with 240 mL of water.
Trial: NCT03729674
Drug: Biosimilar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic-naïve patients starting any biosimilar; patients switching to biosimilar from an alternative biologic therapy; or patients switching to a biosimilar after successfully completing and exiting a previous course of therapy with the equivalent originator drug.
Trial: NCT03729674
Drug: Originator (legacy) drug
RxNorm normalized name: Legacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic-naïve patients starting any originator (legacy) drug; patients switching to an originator drug from an alternative biologic therapy; or patients starting a new cycle with the originator drug.
Trial: NCT00075023
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00176605
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
Trial: NCT01321710
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
Trial: NCT04817904
Drug: Rosuvastatin 10mg
RxNorm normalized name: ROSUVASTATIN 10MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The statin-treated arm will receive Rosuvastatin tablets 10 mg/day starting from the point of cisplatin initiation through the entire duration of therapy
Trial: NCT02236520
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02236520
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01083784
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group
Trial: NCT02236520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 1)
RxNorm normalized name: rosuvastatin and valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Trial: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 2)
RxNorm normalized name: rosuvastatin and valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Trial: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 3)
RxNorm normalized name: rosuvastatin and valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Trial: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 4)
RxNorm normalized name: valsartan 4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Trial: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 5)
RxNorm normalized name: rosuvastatin 5 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Trial: NCT01609907
Drug: Rosuvastatin+Valsartan (Sequence 6)
RxNorm normalized name: valsartan 6 MG
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
Trial: NCT01910259
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison with placebo
Trial: NCT01910259
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison with placebo
Trial: NCT01910259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT03936556
Drug: Marketed toothpaste
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed stannous fluoride (0.454%) toothpaste
Trial: NCT03936556
Drug: Marketed Cavity Protection Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed sodium monofluorophosphate (0.76 %) toothpaste
Trial: NCT02238275
Drug: Micardis® plus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02152163
Drug: IV Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02152163
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01065610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02705469
Drug: ZEN003694
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00766532
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any aromatase inhibitor started as initial adjuvant therapy
Trial: NCT00381342
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
Trial: NCT01908764
Drug: AL-60371 otic suspension
RxNorm normalized name: acetic acid
DrugBank: Acetic acid (DB03166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01621633
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04575558
Drug: Hydroxychloroquine and Azithromycin
RxNorm normalized name: cefixime and azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400mg PO BID 2 times a day + Azithromycin 500mg PO QD
Trial: NCT04553133
Drug: PF-07104091 monotherapy dose escalation
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07104091 will be administered orally
Trial: NCT04553133
Drug: PF-07104091 monotherapy dose expansion (ovarian)
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07104091 will be administered orally
Trial: NCT04553133
Drug: PF-07104091 monotherapy dose expansion (SCLC)
RxNorm normalized name: Influenza, high-dose, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07104091 will be administered orally
Trial: NCT01836432
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation
Trial: NCT01686620
Drug: BIOD-123
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03553342
Drug: Corticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive corticosteroids therapy: 1mg/kg of prednisolone daily for seven days.
Trial: NCT02698267
Drug: BIIB074
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm
Trial: NCT00209625
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00209625
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00794456
Drug: Passiflora ; Crataegus and Salix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet PO twice a day
Trial: NCT03945526
Drug: Astaxanthine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03945526
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01136174
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID for cohort 1,2,3
Trial: NCT01136174
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
Trial: NCT03727620
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients were administered 200 mg of Longamycine the first day and 100 mg per day for 14 days
Trial: NCT01549080
Drug: Yisuishengxue Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
Trial: NCT00354770
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT03158675
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
Trial: NCT00876187
Drug: Placebo for naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo for naproxen twice a day for 16 weeks
Trial: NCT00876187
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral naproxen 500 mg twice a day for 16 weeks
Trial: NCT03882814
Drug: Placebo - Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular saline was administered to the control group as placebo. Salin intramuscular (IM) injection was performed when cervical dilatation was at or greater than 4 cm and the cardiotocogram uterine contraction recordings of 200 Montevideo units was reached. salon was given following amniotomy.
Trial: NCT00848055
Drug: AbGn168 intravenous infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose intravenous infusion
Trial: NCT00848055
Drug: AbGn168 subcutaneous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose subcutaneous injection
Trial: NCT04536688
Drug: RGLS4326
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for subcutaneous injection
Trial: NCT00801879
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
Trial: NCT01072214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT01381432
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
Trial: NCT00001498
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00001498
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00001498
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00001498
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02173574
Drug: EDP239
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00331045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01765920
Drug: Ergoferon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml 3 times a day
Trial: NCT01765920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml 3 times a day